RecruitingPhase 2NCT03774446

Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

Studying Cushing disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Cedars-Sinai Medical Center
Principal Investigator
Shlomo Melmed, MD, M.D
Cedars-Sinai Medical Center
Intervention
Seliciclib(drug)
Enrollment
13 enrolled
Eligibility
18 years · All sexes
Timeline
20182026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03774446 on ClinicalTrials.gov

Other trials for Cushing disease

Additional recruiting or active studies for the same condition.

See all trials for Cushing disease

← Back to all trials